Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Overview
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Athenex Inc
Nuvectis Pharma Inc
Pulmatrix Inc
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Drug Profiles
KX-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXP-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PUR-1800 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit C Src Kise for Colon Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CSK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Src Tyrosine Kise for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tirbanibulin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UM-164 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Sep 27, 2021: Almirall launches Klisyri(Tirbanibulin) for the treatment of actinic keratosis in Europe
Jul 19, 2021: Almirall receives European Commission approval of Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis
May 21, 2021: Almirall receives positive CHMP opinion for Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis
Apr 12, 2021: Pulmatrix to regain full rights to PUR1800 and rrow spectrum kise inhibitor portfolio
Mar 04, 2021: Pulmatrix provides update on its lung cancer drug candidate PUR-1800
Feb 18, 2021: Almirall U.S. launches Klisyri (tirbanibulin), a new, innovative topical treatment for actinic keratosis
Feb 18, 2021: Athenex announces U.S. launch of Klisyri and licensing of additiol territories for tirbanibulin
Feb 11, 2021: Athenex announces New England Jourl of Medicine publication of phase III data on the efficacy and safety of Klisyri (tirbanibulin)
Dec 15, 2020: Almirall announces FDA approval of Klisyri (tirbanibulin), a new innovative topical treatment for actinic keratosis
Mar 09, 2020: Athenex announces FDA acceptance for filing of U.S. NDA for tirbanibulin ointment in actinic keratosis
Mar 02, 2020: Athenex’s partner Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for tirbanibulin ointment in actinic keratosis
Oct 28, 2019: Athenex announces progress update from partner Almirall on Tirbanibulin Ointment
Sep 11, 2019: Athenex announces initiation of phase I clinical study in chi of KX2-36 oral by partner Guangzhou Xiangxue pharmaceutical
Jun 06, 2019: Athenex and PharmaEssentia announce positive early sigls of clinical activity of KX2-391 (INN: tirbanibulin) in patients with Psoriasis
Mar 04, 2019: Athenex announces positive topline results from two phase III studies of KX2-391 ointment 1% featured in late breaker program at the 2019 American Academy of Dermatology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Athenex Inc, 2021
Pipeline by Nuvectis Pharma Inc, 2021
Pipeline by Pulmatrix Inc, 2021
Dormant Projects, 2021
Discontinued Products, 2021